NASCENT BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0998 USD | 0.00% |
|
-0.10% | -42.28% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1 1.37 | Sales 2023 | - | Capitalization | 7.16M 9.8M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | -2M -2.74M | EV / Sales 2022 | 6,213,671 x |
| Net cash position 2022 | 94.41K 129K | Net Debt 2023 | 217K 298K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-13.1
x | P/E ratio 2023 |
-2.38
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -0.10% | ||
| Current month | -0.10% | ||
| 1 month | -16.83% | ||
| 3 months | -20.16% | ||
| 6 months | -30.93% | ||
| Current year | -42.28% |
1 week
0.08
0.10
1 month
0.080.12
Current year
0.080.19
1 year
0.030.28
3 years
0.030.45
5 years
0.030.45
10 years
0.031.62
| Managers | Title | Age | Since |
|---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 0.0998 | 0.00% | 23,319 |
| 24-05-02 | 0.0998 | +2.89% | 13,146 |
| 24-05-01 | 0.097 | -2.90% | 152,676 |
| 24-04-30 | 0.0999 | 0.00% | 6,006 |
Delayed Quote OTC Markets, May 06, 2024 at 12:41 pm
More quotes
Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.
| 1st Jan change | Capi. | |
|---|---|---|
| -42.28% | 17.03M | |
| +9.15% | 106B | |
| -1.08% | 104B | |
| +6.17% | 23.25B | |
| -11.55% | 22.5B | |
| -6.68% | 18.7B | |
| -37.08% | 17.95B | |
| -9.91% | 16.99B | |
| +7.55% | 14.26B | |
| +40.04% | 12.76B |
- Stock Market
- Equities
- NBIO Stock